Global Lamellar Ichthyosis Treatment Market - 2023-2030

Global Lamellar Ichthyosis Treatment Market - 2023-2030

Global lamellar ichthyosis treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Lamellar ichthyosis is also known as collodion baby, collodion baby syndrome, or congenital lamellar ichthyosis. It is a rare genetic skin disorder that is present at birth, mainly characterized by cutaneous redness and extensive scaling. It is one of three genetic skin disorders called autosomal recessive congenital ichthyoses (ARCI). This skin disorder is caused by harmful changes in several genes. The most common gene related to this condition is TGM1. Other genes include NIPAL4, ALOX12B, and CYP4F22.

Moreover, lamellar ichthyosis is not life-threatening but causes severe skin disfigurement and there is no proven cure. The main goal of treatment, which mostly addresses symptoms, is to stop excessive transepidermal water loss and subsequent infections. It is usually treated topically by using moisturizing creams containing petrolatum or lanolin, emollients, keratolytic (anti-scaling) creams and others. Antibiotics and retinoids (synthetic vitamin A derivative drugs) are also used in treatment.

Market Dynamics: Drivers

Increasing adoption of topical medications

The increasing adoption of topical medicines and the development of novel and advanced topical medications are expected to drive the market over the forecast period. Topical medicines such as moisturizing creams and others are crucial for managing the visible symptoms of lamellar ichthyosis, such as thick scales on the skin and dry skin. Their ability to provide localized relief contributes to their increased adoption. Many pharmaceutical companies are focussing on the development of novel topical agents.

For instance, on April 28, 2022, Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, cleared that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, for the treatment of X-linked recessive ichthyosis (XRI) and autosomal recessive congenital ichthyosis, lamellar ichthyosis.

Moreover, the increasing prevalence of lamellar ichthyosis is increasing the demand for the topical agents for the better patient outcomes. For instance, according to the National Institute of Health (NIH), lamellar ichthyosis, a rare genetic skin disorder affects all populations, and the prevalence is less than 1 case per 300,000 individuals.

In addition, unlike systemic medications taken orally or by injection, topical medicines have a more localized effect by reducing the risk of systemic side effects. This makes them a preferred choice for long-term use in the treatment of lamellar ichthyosis. Topical medications are known for easier to apply and are more convenient for patients by enhancing treatment adherence. This increases the adoption of topical medications for the treatment of lamellar ichthyosis.

Further, the increasing prevalence of lamellar ichthyosis, increasing clinical trials, increasing awareness, increasing demand for personalized treatment options and advancements in the development of novel drugs and topical therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and adverse effects associated with topical creams and other drugs, the high cost of the treatment, the availability of alternative treatment options and lack of better treatment for the treatment of lamellar ichthyosis are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global lamellar ichthyosis treatment market is segmented based on treatment type, route of administration, distribution channel and region.

The moisturizing creams segment accounted for approximately 53.2% of the lamellar ichthyosis treatment market share

The moisturizing creams segment is expected to hold the largest market share over the forecast period. Usually, there is no cure for lamellar ichthyosis, but moisturizing creams are considered first-line treatment for the management of the symptoms. The primary goal of using moisturizing creams is to provide symptomatic relief. By keeping the skin adequately moisturized, these creams help reduce itching, flaking, and discomfort associated with lamellar ichthyosis.

Moreover, dry and scaly skin in lamellar ichthyosis can lead to cracks and fissures. Moisturizing creams are known to create a protective layer on the skin, preventing these fissures from forming and minimizing the risk of infection. Regular use of moisturizing creams contributes to an improvement in skin texture. The scales may become less prominent, and the skin may feel smoother, enhancing the overall appearance.

Many moisturizing creams used for lamellar ichthyosis are available over the counter, making them easily accessible to patients without the need for a prescription. This accessibility contributes to their widespread use. In addition, their wide adoption also increases the demand for moisturizing creams.

Geographical Analysis

North America accounted for approximately 38.4% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing research activities and advanced healthcare facilities. North America especially in the United States, boasts advanced healthcare infrastructure, including state-of-the-art medical facilities, specialized clinics, and well-established healthcare facilities. These facilities support the treatment and management of lamellar ichthyosis. Advanced healthcare infrastructure enhances accessibility to advanced therapies and contributes to the overall market growth.

The increasing prevalence in the region is expected to increase the demand for the market. For instance, according to the National Institutes of Health, lamellar ichthyosis is estimated to affect 1 in 100,000 individuals in the United States.

Furthermore, the United States is home to numerous research institutions, pharmaceutical companies, and academic centers. The region's robust research activities contribute to advancements in understanding lamellar ichthyosis and developing novel treatment options for better patient outcomes. Ongoing research fosters innovation and the discovery of new therapies, which can positively impact the market in the region.

Competitive Landscape

The major global players in the lamellar ichthyosis treatment market include LGM Pharma, Mylan Inc., Sebapharma GmbH & Co. KG, Timber Pharmaceuticals LLC, Galderma SA, Beiersdorf AG, DFB Technology, Ltd., Unilever PLC, LANOLIPS PTY LTD and Lanolin Beauty International among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global lamellar ichthyosis treatment market. During the pandemic, the ongoing clinical trials and research activities are temporarily disrupted due to the redirected focus on the COVID-19 pandemic and its related restrictions. Many research institutions and pharmaceutical companies faced challenges in conducting trials, enrolling participants, and ensuring the continuity of research activities. This could have delayed the development of new treatments for lamellar ichthyosis. The pandemic also disrupted the supply chain of these treatment medicines globally.

Why Purchase the Report?
• To visualize the global lamellar ichthyosis treatment market segmentation based on treatment type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of lamellar ichthyosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global lamellar ichthyosis treatment market report would provide approximately 61 tables, 61 figures, and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies